In the NHL group, 61.90% (13/21) had BLs, 28.57% (6/21) DLBCLs, 4.76% (1/21) ALCL CD30+/ALK+, and 4.76% (1/21) PTCL. This evidence concerns the gene ALK and mature T-cell and NK-cell non-Hodgkin lymphoma.